Azurrx biopharma, inc. (AZRX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15
Research and development expenses

7,224

8,680

9,957

8,916

7,103

5,771

3,923

3,721

3,539

2,395

2,469

2,247

2,344

2,496

0

0

0

0

General and administrative expenses

5,844

6,063

7,709

7,154

7,128

7,450

7,521

8,213

7,427

7,685

7,604

6,138

5,641

4,129

0

0

0

0

Fair value adjustment, contingent consideration

-

-

30

-50

-

-210

-270

60

-30

-140

1,090

-60

200

300

0

0

0

0

Loss from operations

0

-

-17,636

-16,120

0

-

-11,715

-11,875

-10,997

-10,221

-8,983

-8,445

-7,786

-6,325

0

0

0

0

Other:
Interest expense

2,709

433

279

174

110

101

279

681

922

875

4,807

5,123

5,224

5,937

0

0

0

0

Fair value adjustment, warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,329

0

0

0

0

Total other

2,709

433

279

174

110

101

279

681

922

875

5,262

5,864

7,623

8,266

0

0

0

0

Loss before income taxes

0

-

0

0

0

-

0

0

0

-

-14,246

-14,310

-15,409

-14,591

0

0

0

0

Income taxes

0

-

0

0

0

-

0

0

0

-

0

0

0

0

0

0

0

0

Net loss

-15,778

-15,177

-17,915

-16,295

-14,561

-13,533

-11,994

-12,557

-11,920

-11,096

-14,246

-14,310

-15,409

-14,591

0

0

0

0

Other comprehensive loss:
Foreign currency translation adjustment

136

-116

-261

-159

-395

-194

-365

110

550

506

483

107

-248

-115

0

0

0

0

Total comprehensive loss

-15,641

-15,294

-18,177

-16,454

-14,957

-13,728

-12,359

-12,446

-11,369

-10,590

-13,763

-14,203

-15,658

-14,707

0

0

0

0

Basic and diluted weighted average shares outstanding

26,941

-63,162

24,962

20,479

17,719

-44,637

16,889

15,300

12,447

11,576

11,242

10,064

9,631

9,264

6,028

5,999

4,725

3,587

Loss per share - basic and diluted

-0.20

22,425,564.68

-0.17

-0.25

-0.26

15,439,310.66

-0.15

-0.22

-0.29

-0.20

-0.28

-0.27

-0.29

-0.66

-0.53

-0.63

-0.42

-0.52